University students with cystic fibrosis (CF) are invited to apply to AbbVie’s CF Scholarship program and a chance to receive up to $25,000 for the upcoming school year. The program supports U.S. residents with CF…
News
Long-term treatment with Kalydeco (ivacaftor) in people with cystic fibrosis (CF) is associated with a better body mass index, lung function, and a lesser effort required to breath, a small study reports. The single-site study, “Long‐term…
Most healthcare professionals are not fully prepared for cystic fibrosis (CF) end-of-life care, and further training and coordination between CF and palliative care teams would be helpful, according to a small, single-center survey in the U.K. Its researchers recommended a broader survey — one nationwide, or even international — to…
An unusual clinical presentation can hinder proper diagnosis for people with cystic fibrosis (CF), even with newborn screening, a new case report contends. The report, “Uncommon clinical presentation of cystic fibrosis in a patient homozygous for a rare CFTR mutation: a case report,” was published in…
When it comes to lung transplants, a study has found that the practice of many cystic fibrosis (CF) specialists differs from that of updated recommendations, highlighting a need to educate providers on new guidelines. The study, “Lung transplant referral practice patterns: a survey of cystic fibrosis physicians and general…
Savara Pharmaceuticals has stopped patient enrollment into two of its ongoing clinical trials in cystic fibrosis (CF) patients — AVAIL and ENCORE — for safety reasons due to the COVID-19 pandemic. Steps will also be taken to ensure that those already enrolled in both studies continue…
ReCode Therapeutics has raised $80 million in Series A financing to support the preclinical development of its lead targeted RNA therapy for cystic fibrosis (CF). The funding also will be used to support the development of RNA therapies for primary ciliary dyskinesia (PCD), a hereditary condition that impairs the function…
Translate Bio‘s therapy MRT5005 has been given a rare pediatric disease designation by the U.S. Food and Drug Administration (FDA) for the treatment of cystic fibrosis in children, while its ongoing clinical trial investigating the therapy in adult patients faces delays due to the COVID-19…
Eloxx Pharmaceuticals has temporarily paused enrollment in Phase 2 clinical trials of ELX-02 in cystic fibrosis (CF) patients in response to the COVID-19 pandemic. According to Eloxx,…
Problems with the CFTR protein in platelets, blood cells essential to clotting, activated these cells, both driving lung inflammation and injury, and hindering the lungs’ ability to clear bacteria in a mouse models of cystic fibrosis (CF), a study found. Blocking a calcium channel known as TRPC6 returned platelets…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Inhaled therapy ETD001 well tolerated in healthy volunteers December 15, 2025
- This winter solstice, I reflect on moving from darkness to light December 12, 2025
- Safety concerns halt BX004 phage therapy trial for CF infection December 9, 2025
- Trikafta cuts need long-term for other CF treatments in real world December 8, 2025
- We shouldn’t have to fight so hard for healthcare coverage December 8, 2025